Jens Verheyen

List of Publications by Year
in descending order

36 papers	968 citations	471477 17 h-index	454934 30 g-index
37 all docs	37 docs citations	37 times ranked	1788 citing authors

#	Article	IF	Citations
1	Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo. Journal of Virology, 2016, 90, 6001-6013.	3.4	114
2	Detection of Adenoviruses and Rotaviruses in Drinking Water Sources Used In Rural Areas of Benin, West Africa. Applied and Environmental Microbiology, 2009, 75, 2798-2801.	3.1	84
3	Hepatitis E Virus Infection as a Possible Cause of Acute Liver Failure in Europe. Clinical Gastroenterology and Hepatology, 2015, 13, 1836-1842.e2.	4.4	83
4	A new ensemble coevolution system for detecting HIV-1 protein coevolution. Biology Direct, 2015, 10, 1.	4.6	78
5	Liver Failure due to Acute Viral Hepatitis (A-E). Visceral Medicine, 2016, 32, 80-85.	1.3	65
6	Compensatory Mutations at the HIV Cleavage Sites P7/P1 and P1/P6-Gag in Therapy-Naive and Therapy-Experienced Patients. Antiviral Therapy, 2006, 11, 879-888.	1.0	58
7	Extraction of viral nucleic acids: Comparison of five automated nucleic acid extraction platforms. Journal of Clinical Virology, 2012, 54, 255-259.	3.1	54
8	Rapid Rebound of a Preexisting CXCR4-tropic Human Immunodeficiency Virus Variant After Allogeneic Transplantation With CCR5 Î”32 Homozygous Stem Cells. Clinical Infectious Diseases, 2019, 68, 684-687.	5.8	42
9	Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. BMC Infectious Diseases, 2018, 18, 251.	2.9	33
10	High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. Aids, 2010, 24, 669-673.	2.2	32
11	Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antiviral Therapy, 2006, 11, 879-87.	1.0	32
12	The detection of HBsAg mutants expressed in vitro using two different quantitative HBsAg assays. Journal of Clinical Virology, 2012, 54, 279-281.	3.1	31
13	Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapyâ€“Experienced Patients in Europe (CAPRE). Journal of Infectious Diseases, 2016, 213, 39-48.	4.0	28
14	Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naÃ¯ve patients. Journal of Infection, 2009, 58, 61-67.	3.3	22
15	Clinical performance of the novel DiaSorin LIAISONÂ® XL murex: HBsAg Quant, HCV-Ab, HIV-Ab/Ag assays. Journal of Clinical Virology, 2014, 59, 44-49.	3.1	22
16	Genotyping hepatitis B virus dual infections using population-based sequence data. Journal of General Virology, 2012, 93, 1899-1907.	2.9	19
17	Clinical Outcome and Viral Genome Variability of Hepatitis B Virusâ€“Induced Acute Liver Failure. Hepatology, 2019, 69, 993-1003.	7.3	19
18	HIV-1 persistent viremia is frequently followed by episodes of low-level viremia. Medical Microbiology and Immunology, 2017, 206, 203-215.	4.8	17

#	Article	IF	Citations
19	Impact of lowâ€level <scp>BK</scp> polyomavirus viremia on intermediateâ€term renal allograft function. Transplant Infectious Disease, 2018, 20, e12817.	1.7	17
20	Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable. Journal of Hepatology, 2015, 63, 13-19.	3.7	16
21	Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies. Journal of Clinical Virology, 2017, 93, 46-52.	3.1	13
22	Impact of immune suppressive agents on the BK-Polyomavirus non coding control region. Antiviral Research, 2018, 159, 68-76.	4.1	12
23	Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. Journal of Infection, 2015, 70, 288-298.	3.3	11
24	No SEVI-mediated enhancement of rectal HIV-1 transmission of HIV-1 in two humanized mouse cohorts. Virology, 2016, 488, 88-95.	2.4	11
25	The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation. Journal of Clinical Virology, 2019, 113, 14-19.	3.1	8
26	A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro. Viruses, 2020, 12, 251.	3.3	8
27	Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics. Medical Microbiology and Immunology, 2015, 204, 613-618.	4.8	7
28	Analysis of immune selection as a potential cause for the presence of cleavage site mutation 431V in treatment-naive HIV type-1 isolates. Antiviral Therapy, 2010, 15, 907-912.	1.0	6
29	Clinical and Virological Aspects of HBV Reactivation: A Focus on Acute Liver Failure. Viruses, 2019, 11, 863.	3.3	5
30	Antiretroviral therapy suppresses rectal HIV-RNA shedding despite inflammation in MSM with rectal C. trachomatis and N. gonorrhoeae infectionsâ€"a cross-sectional, single-center study. Sexually Transmitted Infections, 2019, 95, 95-98.	1.9	5
31	Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo , hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. Emerging Microbes and Infections, 2020, 9, 928-939.	6.5	5
32	Clinical patterns associated with the concurrent detection of antiâ€HBs and HBV DNA. Journal of Medical Virology, 2018, 90, 282-290.	5.0	4
33	Inferring Short-Range Linkage Information from Sequencing Chromatograms. PLoS ONE, 2013, 8, e81687.	2.5	3
34	Detection of hepatitis b virus DNA in the blood of a stem cell donor after granulocyte colonyâ€stimulating factor treatment. Hepatology, 2016, 64, 1803-1805.	7.3	2
35	Reduced Frequencies and Activation of Regulatory T Cells After the Treatment of HIV-1-Infected Individuals with the CCR5 Antagonist Maraviroc Are Associated with a Reduction in Viral Loads Rather Than a Direct Effect of the Drug on Regulatory T Cells. Viral Immunology, 2016, 29, 192-196.	1.3	2
36	Time on drug analysis based on real life data. Journal of the International AIDS Society, 2014, 17, 19790.	3.0	0